BioXcel Therapeutics Q2 2023 Earnings Report

BioXcel Therapeutics EPS Results

• Actual EPS: -$29.28
• Consensus EPS: -$27.52
• Beat/Miss: Missed by -$1.76
• One Year Ago EPS: -$21.60

BioXcel Therapeutics Revenue Results

• Actual Revenue: $0.46 million
• Expected Revenue: $0.42 million
• Beat/Miss: Beat by +$40.00 thousand
• YoY Revenue Growth: +45,600.00%

BioXcel Therapeutics Announcement Details

• Quarter: Q2 2023
• Date: 8/14/2023
• Time: Before Market Opens

BioXcel Therapeutics (NASDAQ:BTAI), a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.